A Randomized, Double-Blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg TID) in Patients with Symptomatic Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonias (IIP).
A study for patients with pulmonary hypertension using study drug Riociguat
Sponsor: Bayer
Enrolling: Male and Female Patients
IRB Number: AAAN4757
U.S. Govt. ID: NCT02138825
Contact: Amika McBurnie: 212-342-1518 / akm2192@cumc.columbia.edu
Additional Study Information: The purpose of this study is to study the effects of a new study drug known as Riociguat in people diagnosed with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP). Patients will be in the study for approximately 26 weeks in which they will take the pill Riogciguat three times a day.
This study is closed
Investigator
David Lederer, MD
Do You Qualify?
Do you have a form of idiopathic interstitial pneumonia (IIP)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Amika McBurnie
akm2192@cumc.columbia.edu
212-342-1518
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE